The U.S. Food and Drug Administration (FDA) have approved a new Investigational New Drug (IND) application for a novel cell therapy called CLBR001+SWI0I9 leading to an imminent Phase I clinical trial of a new CAR-T technology centering on “switchable” cells that can...